January 9, 2015 / 1:20 PM / 5 years ago

Portola's drug reverses effect of J&J's blood thinner Xarelto

Jan 9 (Reuters) - Portola Pharmaceuticals Inc said its experimental drug met the main goal of reversing the effect of Johnson & Johnson’s blood thinner, Xarelto, in a late-stage study.

Data showed that an intravenous shot of the drug, andexanet alfa, immediately reversed the anticoagulation activity of Xarelto in healthy volunteers aged 50-75 years.

Further data on the study is expected in mid-2015, Portola said on Friday.

Portola said in October that the drug was effective in reversing the effect of Eliquis, an anti-clotting drug by Bristol-Myers Squibb Co and Pfizer Inc.

Reporting by Natalie Grover in Bengaluru; Editing by Kirti Pandey

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below